PDGF receptors as cancer drug targets.

@article{Pietras2003PDGFRA,
  title={PDGF receptors as cancer drug targets.},
  author={Kristian Pietras and Tobias Sj{\"o}blom and Kristofer Rubin and Carl-Henrik Heldin and Arne Ostman},
  journal={Cancer cell},
  year={2003},
  volume={3 5},
  pages={
          439-43
        }
}
The benefits of combining PDGF antagonists and VEGF antagonists in a mouse model of pancreatic islet cancer are shown in a report by Bergers et al.: Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295. 

Citations

Publications citing this paper.
SHOWING 1-10 OF 226 CITATIONS, ESTIMATED 58% COVERAGE

Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells.

  • Human molecular genetics
  • 2006
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

  • Journal of Neuroimmune Pharmacology
  • 2013
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Tumor lymphangiogenesis and lymphangiogenic growth factors.

  • Archives of medical research
  • 2008
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 12 Highly Influenced Citations

  • Averaged 10 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES